A full-year 2024 trading update for Arecor Therapeutics shows revenue was up to £5.1million (2023: £4.6m) while cash and cash ...

(Alliance News) - Arecor Therapeutics PLC on Monday said its revenue increased in 2024 and said it is excited by the prospects of its "superior insulin candidate". The Cambridgeshire, England-based ...

In the third quarter of 2024, t:slim X2 became compatible with Eli Lilly and Company’s Lyumjev — an ultra-rapid-acting insulin in the European Union. In addition, the company made a ...

Arecor Therapeutics reported total full-year revenue of £5.1m in a trading update on Monday, up from £4.6m in 2023.

Arecor’s own lead product is an ultra-rapid acting insulin, which the company hopes will outperform market rivals from the likes of Eli Lilly, Sanofi and Novo Nordisk. Codenamed AT247 ...

Nova Minerals identifies new high-grade zone with samples up to 52.3 g/t at Estelle Gold and Critical Minerals Project ...

Part of what makes medical emergencies so scary is that, by nature, they can happen completely unexpectedly.